WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317365
Description: Candoxatril is the orally active prodrug of candoxatrilat (UK-73967) human neutral endopeptidase (Neprilysin) as the neutral endopeptidase 24.11 complexed (RB-101) with phosphoramidon degrades and inactivates a number of bioactive peptides. Two multiply connected folding domains of the neutral endopeptidase locus splicing of exons 1, 2a, or 2b to the common exon 3 composed of 24 exons of the human CALLA/NEP gene containing the active site, it is known as peptidase family M13 the gluzincins a faint but significant structural relationship of the metzincins to the thermolysin-like enzymes, Zincin is the simplest descriptor of biological space.
MedKoo Cat#: 317365
Chemical Formula: C29H41NO7
Exact Mass: 515.2883
Molecular Weight: 515.64
Elemental Analysis: C, 67.55; H, 8.01; N, 2.72; O, 21.72
Synonym: UK 79300, UK-79300, UK79300, Candoxatril
IUPAC/Chemical Name: 4-[[1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid
InChi Key: ZTWZVMIYIIVABD-RZMWZJFBSA-N
InChi Code: InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21?,23-,24?/m0/s1
SMILES Code: O=C(C1CCC(NC(C2(C[C@@H](COCCOC)C(OC3=CC4=C(CCC4)C=C3)=O)CCCC2)=O)CC1)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 515.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Singh JS, Lang CC. Angiotensin receptor-neprilysin inhibitors: clinical
potential in heart failure and beyond. Vasc Health Risk Manag. 2015 Jun
1;11:283-95. doi: 10.2147/VHRM.S55630. eCollection 2015. Review. PubMed PMID:
26082640; PubMed Central PMCID: PMC4459540.
2: Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin
system inhibition for the treatment of heart failure. JACC Heart Fail. 2014
Dec;2(6):663-70. doi: 10.1016/j.jchf.2014.09.001. Epub 2014 Oct 8. Review. PubMed
3: Eizenberg Y, Grossman E, Peleg E, Shabtai Z, Sharabi Y. Neutral endopeptidase
inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the
metabolic syndrome. J Am Soc Hypertens. 2014 Apr;8(4):227-31. doi:
10.1016/j.jash.2014.01.006. Epub 2014 Jan 24. PubMed PMID: 24560177.